文献速递肾癌与肾肿瘤

锝-99m-甲氧基异丁基异腈SPECT/CT在常规临床实践中鉴别嗜酸细胞肿瘤与肾细胞癌的性能

Clinical Performance of Technetium-99m-Sestamibi SPECT/CT Imaging in Differentiating Oncocytic Tumors From Renal Cell Carcinoma in Routine Clinical Practice.
PubMed 文献 · J Urol · 2023-06-28

该研究纳入2020年2月至2021年12月接受锝-99m-甲氧基异丁基异腈SPECT/CT评估肾脏肿物的71例患者(88个肿物),比较「热」与「冷」扫描的病理一致性。7个「热」肿物中1例活检不一致(14.3%,透明细胞肾细胞癌);5个活检「冷」肿物中4例(80%)为不一致的嗜酸细胞瘤;切除标本中35/40(87.5%)为肾细胞癌,5/40(12.5%)为不一致的嗜酸细胞瘤。作者认为该影像策略尚不能替代活检,需进一步研究。

要点

  • 71例患者(88个肿物)中,60例(84.5%)至少1个「冷」肿物,11例(15.5%)仅「热」肿物。
  • 7个「热」肿物有病理,1例活检(14.3%)不一致为透明细胞肾细胞癌。
  • 5个活检「冷」肿物中4例(80%)为不一致的嗜酸细胞瘤;切除标本中35/40(87.5%)为肾细胞癌,5/40(12.5%)为不一致的嗜酸细胞瘤。

核心结论

  • 作者认为需要进一步研究以明确锝-99m-甲氧基异丁基异腈在真实世界临床实践中的效用;作者认为该影像策略尚不能替代活检。

研究设计与样本

  • 回顾性纳入2020年2月至2021年12月接受锝-99m-甲氧基异丁基异腈SPECT/CT评估肾脏肿物的患者,共71例(88个肿物)。

主要发现

  • 60例(84.5%)患者至少1个「冷」肿物,11例(15.5%)仅「热」肿物。
  • 7个「热」肿物有病理,1例活检(14.3%)不一致为透明细胞肾细胞癌。
  • 5个活检「冷」肿物中4例(80%)为不一致的嗜酸细胞瘤。
  • 切除标本中35/40(87.5%)为肾细胞癌,5/40(12.5%)为不一致的嗜酸细胞瘤。
  • 20%病理取样的「冷」肿物仍为嗜酸细胞瘤/杂合嗜酸细胞/嫌色细胞肿瘤/嫌色细胞肾细胞癌。

关键数值与推荐

  • 「热」扫描定义为锝-99m-甲氧基异丁基异腈摄取在感兴趣肿物与正常肾实质之间定性相等或更高,提示嗜酸细胞瘤、杂合嗜酸细胞/嫌色细胞肿瘤或嫌色细胞肾细胞癌。

临床怎么用

  • 原文结论认为该影像策略尚不能替代活检,需进一步研究明确其效用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Technetium-99m-sestamibi single-photon emission CT/x-ray CT is an emerging clinical tool to differentiate oncocytic tumors from renal cell carcinomas. We report data from a large institutional cohort of patients who underwent technetium-99m-sestamibi scans during evaluation of renal masses. MATERIALS AND METHODS: Patients who underwent technetium-99m-sestamibi single-photon emission CT/x-ray CT between February 2020 and December 2021 were included in the analysis. Scans were defined as "hot" for oncocytic tumor when technetium-99m-sestamibi uptake was qualitatively equivalent or higher between the mass of interest and normal renal parenchyma, suggesting oncocytoma, hybrid oncocytic/chromophobe tumor, or chromophobe renal cell carcinoma. Demographic, pathological, and management strategy data were compared between "hot" and "cold" scans. For individuals who underwent diagnostic biopsy or extirpative procedures, the concordance between radiological findings and pathology was indexed. RESULTS: A total of 71 patients (with 88 masses) underwent technetium-99m-sestamibi imaging with 60 (84.5%) patients having at least 1 "cold" mass on imaging and 11 (15.5%) patients exhibiting only "hot" masses. Pathology was available for 7 "hot" masses, with 1 biopsy specimen (14.3%) being discordant (clear cell renal cell carcinoma). Five patients with "cold" masses underwent biopsy. Out of 5 biopsied masses, 4 (80%) were discordant oncocytomas. Of the extirpated specimens, 35/40 (87.5%) harbored renal cell carcinoma and 5/40 (12.5%) yielded discordant oncocytomas. In sum, 20% of pathologically sampled masses that were "cold" on technetium-99m-sestamibi imaging still harbored oncocytoma/hybrid oncocytic/chromophobe tumor/chromophobe renal cell carcinoma. CONCLUSIONS: Further work is needed to define utility of technetium-99m-sestamibi in real-world clinical practice. Our data suggest this imaging strategy is not yet ready to replace biopsy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Schober JP, Braun A, Ginsburg KB, et al. Clinical Performance of Technetium-99m-Sestamibi SPECT/CT Imaging in Differentiating Oncocytic Tumors From Renal Cell Carcinoma in Routine Clinical Practice. J Urol. 2023. PMID: 37378576. doi:10.1097/JU.0000000000003557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。